Form 10-Q Denali Therapeutics Inc. For: Mar 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Denali Therapeutics Inc. (DNLI) PT Lowered to $22 at Stifel
May 8, 2024 6:17 AM EDTStifel analyst Paul Mattels lowered the price target on Denali Therapeutics Inc. (NASDAQ: DNLI) to $22.00 (from $26.00) while maintaining a Hold rating.
The analyst comments "Most importantly, DNLI is noting now that CDER "may be open to discussing an accelerated path" for... More
